BRAIN BIOTECH AG | Company Presentation | Michael Schneiders, Investor Relations

Welcome to seat11a, in today’s video we are presenting Michael Schneiders, Head of Investor Relations of BRAIN Biotech AG

Michael will present a detailed company presentation of BRAIN

▶️ Visit us: https://seat11a.com/

▶️ In this video Michael explains:
00:00 BRAIN Biotech AG
00:33 BRAIN in the center of Mega-Trends
03:38 Production Setup
04:20 Value Creation and Synergies
05:32 UN-Sustainable Development Goals
05:59 New Business Pipeline
06:33 CRISPR Cas9 Revolution
09:46 Guidance and Midterm Targets
10:14 Shareholder Structure
10:49 Six Reasons to Invest in Brain
12:03 Contact Brain


Company Profile
BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.

The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.

As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.

Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).



----------------------------
▶️ Visit us: https://seat11a.com/
----------------------------

▶️ Other videos:
Elevator Pitch: https://seat11a.com/investor-relation...
Company Presentation: https://seat11a.com/investor-relation...
Deep Dive Presentation: https://seat11a.com/investor-relation...
Financial Results Presentation: https://seat11a.com/investor-relation...
ESG Presentation: https://seat11a.com/investor-relation...

-----------------------------
▶️ About seat11a:
Seat11a is the next-generation roadshow for listed companies. We democratize financial intelligence by offering listed companies an investor video platform to address their message to Institutional and Professional Investors anywhere, anytime.
-----------------------------




✅ Disclaimer:
this publication is just for informational purposes only – it is not considered to give any investment advice! You agree to www.seat11a.com/legal/ and www.seat11a.com/imprint/